Mirikizumab Is Effective and Safe for Elderly Patients with Ulcerative Colitis

Professor Andreas Sturm, Chief of the Department of Gastroenterology at DRK Kliniken Berlin, presents data from a subanalysis study of the LUCENT-1 and LUCENT-2 trials showing that the IL-23 inhibitor mirikizumab is both effective and safe for treating ulcerative colitis,in elderly patients. This treatment offers a promising alternative to steroids, with fewer side effects and high efficacy.